Sinphar Pharmaceutical (Taiwan) Buy Hold or Sell Recommendation
| 1734 Stock | TWD 30.85 0.25 0.82% |
Assuming the 90 days trading horizon and your bold attitude towards risk, our recommendation regarding Sinphar Pharmaceutical Co is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Sinphar Pharmaceutical Co given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Sinphar Pharmaceutical Co, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Sinphar Pharmaceutical Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Sinphar and provide practical buy, sell, or hold advice based on investors' constraints. Sinphar Pharmaceutical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Sinphar |
Execute Sinphar Pharmaceutical Buy or Sell Advice
The Sinphar recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sinphar Pharmaceutical Co. Macroaxis does not own or have any residual interests in Sinphar Pharmaceutical Co or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sinphar Pharmaceutical's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Almost neglects market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Sinphar Pharmaceutical Trading Alerts and Improvement Suggestions
| Sinphar Pharmaceutical generated a negative expected return over the last 90 days | |
| The company reported the revenue of 2.43 B. Net Loss for the year was (38.13 M) with profit before overhead, payroll, taxes, and interest of 888.71 M. | |
| About 20.0% of the company shares are owned by insiders or employees |
Sinphar Pharmaceutical Returns Distribution Density
The distribution of Sinphar Pharmaceutical's historical returns is an attempt to chart the uncertainty of Sinphar Pharmaceutical's future price movements. The chart of the probability distribution of Sinphar Pharmaceutical daily returns describes the distribution of returns around its average expected value. We use Sinphar Pharmaceutical Co price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sinphar Pharmaceutical returns is essential to provide solid investment advice for Sinphar Pharmaceutical.
| Mean Return | -0.27 | Value At Risk | -2.31 | Potential Upside | 0.98 | Standard Deviation | 1.97 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sinphar Pharmaceutical historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sinphar Pharmaceutical Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sinphar Pharmaceutical or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sinphar Pharmaceutical's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sinphar stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.23 | |
β | Beta against Dow Jones | -0.41 | |
σ | Overall volatility | 0.62 | |
Ir | Information ratio | -0.2 |
Sinphar Pharmaceutical Volatility Alert
Sinphar Pharmaceutical Co exhibits very low volatility with skewness of -1.27 and kurtosis of 15.83. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Sinphar Pharmaceutical's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Sinphar Pharmaceutical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Sinphar Pharmaceutical Fundamentals Vs Peers
Comparing Sinphar Pharmaceutical's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sinphar Pharmaceutical's direct or indirect competition across all of the common fundamentals between Sinphar Pharmaceutical and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sinphar Pharmaceutical or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sinphar Pharmaceutical's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sinphar Pharmaceutical by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sinphar Pharmaceutical to competition |
| Fundamentals | Sinphar Pharmaceutical | Peer Average |
| Return On Equity | 0.0444 | -0.31 |
| Return On Asset | 0.0207 | -0.14 |
| Profit Margin | 0.07 % | (1.27) % |
| Operating Margin | 0.07 % | (5.51) % |
| Current Valuation | 6.26 B | 16.62 B |
| Shares Outstanding | 167.72 M | 571.82 M |
| Shares Owned By Insiders | 20.27 % | 10.09 % |
| Shares Owned By Institutions | 1.49 % | 39.21 % |
| Price To Earning | 536.84 X | 28.72 X |
| Price To Book | 1.88 X | 9.51 X |
| Price To Sales | 2.15 X | 11.42 X |
| Revenue | 2.43 B | 9.43 B |
| Gross Profit | 888.71 M | 27.38 B |
| EBITDA | 109.64 M | 3.9 B |
| Net Income | (38.13 M) | 570.98 M |
| Cash And Equivalents | 937.43 M | 2.7 B |
| Cash Per Share | 5.59 X | 5.01 X |
| Total Debt | 1.49 B | 5.32 B |
| Debt To Equity | 51.50 % | 48.70 % |
| Current Ratio | 2.25 X | 2.16 X |
| Book Value Per Share | 17.41 X | 1.93 K |
| Cash Flow From Operations | 135.54 M | 971.22 M |
| Earnings Per Share | 1.18 X | 3.12 X |
| Number Of Employees | 26 | 18.84 K |
| Beta | 0.79 | -0.15 |
| Market Capitalization | 5.4 B | 19.03 B |
| Total Asset | 6.22 B | 29.47 B |
| Retained Earnings | 237 M | 9.33 B |
| Working Capital | 1.28 B | 1.48 B |
| Current Asset | 2.28 B | 9.34 B |
| Current Liabilities | 999 M | 7.9 B |
| Z Score | 1.8 | 8.72 |
| Annual Yield | 0.01 % |
Sinphar Pharmaceutical Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sinphar . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Sinphar Pharmaceutical Buy or Sell Advice
When is the right time to buy or sell Sinphar Pharmaceutical Co? Buying financial instruments such as Sinphar Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Sinphar Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Chemicals Thematic Idea Now
Chemicals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Chemicals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Chemicals Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Sinphar Stock Analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.